Among 5,243 patients, we excluded patients for whom PSA >10 ng/ml, those who had repeat PBx, those for whom the number of PBx cores <12, those who had other cancers, such as transitional cell carcinoma, on PBx pathology, and those for whom data were missing. This evidence concerns the gene KLK3 and cancer.